Latest Headlines

Latest Headlines

Optimer antibiotic cuts C diff relapse rate

Researchers say that a new antibiotic from Optimer works significantly better than the industry standard vancomycin in combating a relapse of Clostridium difficile. In a 629-patient study

Optimer shares buoyed by promising Ph3 C. diff data

Shares of Optimer Pharmaceuticals zoomed up 20 percent after the developer announced another set of promising data from a large, late-stage study of its experimental antibiotic, fidaxomicin. And the

FDA backs Theravance antibiotic, rejects Targanta's

Theravance won the crucial backing of an FDA advisory committee for its new antibiotic for serious skin infections. The panel voted 21 to 5 to recommend approval of telavancin, which is also designed